The follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common type of papillary thyroid carcinoma (PTC) and accounts for 5%--41% of all PTC subtypes \[[@b1-jptm-2019-09-18]-[@b4-jptm-2019-09-18]\]. FVPTC comprises two major subtypes: infiltrative FVPTC and encapsulated FVPTC (EFVPTC) \[[@b5-jptm-2019-09-18]\]. The incidence of EFVPTC has gradually increased over the past two decades and constitutes more than 10% of all thyroid malignances diagnosed in North America and Europe \[[@b6-jptm-2019-09-18]\]. EFVPTC can be further classified into two subtypes: invasive EFVPTC and non-invasive EFVPTC based on the status of capsular or vascular tumor invasion \[[@b7-jptm-2019-09-18]\]. The majority of non-invasive EFVPTCs behave as indolent non-malignant tumors and have been renamed as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) \[[@b8-jptm-2019-09-18]\]. This introduction of NIFTP concept has significantly affected clinical practice by reducing the therapeutic intensity for patients with EFVPTCs.

Differentiating NIFTP from invasive EFVPTC solely based on cytomorphologic findings is impossible when using thyroid fine needle aspiration cytology. NIFTPs are mostly interpreted as indeterminate categories \[[@b9-jptm-2019-09-18]\]. The two most common genetic mutations found in thyroid tumors are *BRAF* and *RAS* point mutations \[[@b10-jptm-2019-09-18]\]. *RAS* mutations occur in 30%--40% of EFVPTCs \[[@b11-jptm-2019-09-18]-[@b14-jptm-2019-09-18]\]. The *BRAF*^V600E^ mutation is absent in NIFTPs but can occur in up to 30% of invasive EFVPTCs \[[@b14-jptm-2019-09-18],[@b15-jptm-2019-09-18]\].

In Korea, a low rate of NIFTP has been reported in several studies \[[@b16-jptm-2019-09-18]-[@b18-jptm-2019-09-18]\]. However, the studies were limited by small sample size and single institution, and the results might not represent the general population. Therefore, in the present study, the prevalence of NIFTP among Korean patients was evaluated by reviewing multicenter-based data using the largest cohort size to date in Korea.

MATERIALS AND METHODS
=====================

Study cohort
------------

Data from 18,819 patients with PTC from eight university hospitals were retrospectively analyzed. The tumors were diagnosed from surgically resected specimens between January 2012 and February 2018. The slides of all cases initially diagnosed as EFVPTC on pathology reports were reviewed and reclassified into NIFTP, invasive EFVPTC, and other PTC subtypes. The NIFTP was diagnosed according to the criteria of *World Health Organization* (*WHO*) *Classification of Tumours of Endocrine* \[[@b19-jptm-2019-09-18]\] and recently revised diagnostic criteria \[[@b20-jptm-2019-09-18]\]: (1) encapsulation or clear demarcation of the tumors (thick, thin, or partial capsule, or well circumscribed with a clear demarcation from adjacent thyroid tissues), (2) follicular growth pattern with no papillae (including microfollicular, normofollicular, or macrofollicular architecture with abundant colloid) with no psammoma bodies and \<30% solid/trabecular/insular growth pattern, (3) nuclear score 2--3, (4) no capsular or vascular invasion (requires adequate microscopic examination of the tumor capsule interface), (5) no tumor necrosis, (6) no high mitotic activity (high mitotic activity defined as at least 3 mitoses per 10 high-power fields (400×) ([Fig. 1](#f1-jptm-2019-09-18){ref-type="fig"}). A nuclear score of 2--3 is diagnostic of NIFTP. However, if florid nuclear features (nuclear score 3) of PTC are present, a meticulous histopathologic examination of the entire tumor is required for the detection of any true papillae, psammoma bodies, aggressive histology, or invasion into tumor capsule or vessels.

Molecular analysis of *NRAS* and *HRAS* genes
---------------------------------------------

Molecular analysis of 27 NIFTP cases obtained from a single institution was performed. Genomic DNA was extracted from paraffin-embedded thyroid specimen blocks. The representative slides were selected and the tumor tissues were manually dissected under a stereomicroscope and stored in a 1.5 mL tube. Genomic DNAs were extracted from 5--10-μm-thick tissue sections using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Exon 3 of *NRAS* and *HRAS* genes was amplified using polymerase chain reaction (PCR) with the following primers: (1) *NRAS*-exon 3--197 bp, forward (5\'-CCCCTTACCCTCCACACC-3\') and reverse (5\'-GAGGTTAATATCCGCAAATGACTT-3\'); (2) *HRAS*-exon 3--201 bp, forward (5\'-GTCCTCCTGCAGGATTCCTA-3\') and reverse (5\'-CGGGGTTCACCTGTACT-3\'). The PCR cycling conditions for *NRAS* and *HRAS* mutations were as follows: initial activation at 94°C for 15 minutes; 35 cycles at 94°C for 30 seconds, 51°C--57°C for 30 seconds, 72°C for 30 seconds, final extension at 72°C for 10 minutes. The amplicons were analyzed using 2% agarose gel electrophoresis and purified using QIAquick PCR purification kit (Qiagen). The amplified PCR products were sequenced using Sanger sequencing. The amplicons were evaluated on 2% agarose gel electrophoresis and purified using the QIAquick PCR purification kit (Qiagen). The amplified PCR products were analyzed using the automated sequencing machine ABI 3730 (Applied Biosystems, Foster City, CA, USA), which performed Sanger sequencing using the same PCR primers \[[@b17-jptm-2019-09-18]\].

Molecular analysis of *KRAS* gene
---------------------------------

For detection of the *KRAS* mutation, a PNAClamp *KRAS* mutation detection kit (Panagene, Daejeon, Korea) was used. The following reagents were used in all PCR reactions (total volume, 20 µL): 10 ng template DNA, primer, peptide nucleic acid (PNA) probe set, and SYBR Green PCR Master Mix. A CFX 96 (Bio-Rad, Hercules, CA, USA) was used for the real-time PCR of PNA-mediated clamping. PCR cycling conditions consisted of the following sequential steps: 5-minute hold at 94°C followed by 40 cycles at 94°C for 30 seconds, 70°C for 20 seconds, 63°C for 30 seconds, and 72°C for 30 seconds. All seven mutations in the *KRAS* gene were detected using one-step PNA-mediated real-time PCR clamping. PNA probes and DNA primers were used for the corresponding clamping reaction. SYBR Green fluorescent dye was applied for the detection of positive reaction signals. The amplification of the wild-type target was suppressed by the PNA probe sequence complementary to wild-type DNA. Due to this suppression, the amplification of mutant sequences was specifically preferred by competitive inhibition of DNA primers binding to wild-type DNA. The threshold cycle (Ct) value was used to evaluate PCR efficiency. The SYBR Green amplification plots were generated to analyze Ct values for the control and mutation assays. Mutation status was determined by Ct value differences ≥2, which were obtained between the control and samples.

Molecular analysis of *BRAF* gene
---------------------------------

Mutational analysis of *BRAF* was performed using two different methods. The PNAClamp *BRAF* mutation detection kit (Panagene) was used to detect the *BRAF*^V600E^ mutation. Each reaction tube had a total volume of 20 µL and included a mixture of template DNA, primers, PNA probe, and SYBR Green PCR Master Mix. Real-time PCR of PNA-clamping PCR was performed using a CFX96 real-time PCR system (Bio-Rad, Pleasanton, CA, USA). The PNA probe was complementary to wild-type (V600). PCR was performed under the following conditions: 5-minute hold at 94°C, 40 cycles of 30 seconds at 94°C, 20 seconds at 70°C, 30 seconds at 63°C, and 30 seconds at 72°C. The PNA probe and primers incorporated in the assay were separate oligonucleotides, and the PNA probe location was placed between forward and reverse primers within the template. Intercalation of SYBR Green fluorescent dye was used to detect positive signals.

Pyrosequencing for the *BRAF* mutation analysis was performed as described in detail elsewhere \[[@b21-jptm-2019-09-18]\]. The primers used for PCR were the following: forward primer (5\'-GAAGACCTCACAGTAAAAATAG-3\') and reverse primer (5\'-biotin-ATAGCCTCAATTCTTACCATCC-3\'). The pyrosequencing reaction was performed with a sequencing primer (5\'-biotin-ATAGCCTCAATTCTTACCATCC-3\') on a Pyromark Q24 instrument (Qiagen). The PyroMark Q24 software (Qiagen) was used for analysis of the pyrogram results.

Statistical analysis
--------------------

Clinicopathological parameters of NIFTP before and after NIFTP introduction were analyzed using the chi-square test or Fisher's exact test for categorical variables and the t-test for continuous variables. All statistical analyses were performed using SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). A p-value of \<0.05 was considered statistically significant.

Ethics statement
----------------

The current study was approved by the Institutional Review Boards (IRBs) of eight institutions. Ethics approval for all procedures performed in the current study was obtained from the IRB (approval No. 3-2018-0271). Formal written informed consent was waived by the IRB.

RESULTS
=======

The prevalence of NIFTP in PTC cases
------------------------------------

To evaluate the incidence of NIFTP in the Korean population, data were retrospectively collected from the eight university hospitals in Korea. The incidence of NIFTP in each institution is shown in [Table 1](#t1-jptm-2019-09-18){ref-type="table"}. After reviewing pathology reports of 18,819 patients with PTC, 378 patients (2.0%) were initially diagnosed with non-invasive EFVPTC as potential NIFTP cases; 140 cases were excluded from NIFTP diagnosis after review of pathology slides acquired from 378 cases. The most common reason for exclusion was the presence of small, but true papillae that were rediagnosed as conventional PTC. Other reasons for exclusion were reclassification as infiltrative FVPTC or unavailability for slide review. Finally, 238 (1.3%) of all PTCs were eligible for the diagnosis of NIFTP after slide review.

Among 238 cases of NIFTP, 174 cases (73.3%) had only NIFTP; in the remaining 64 cases (26.7%), NIFTP coexisted with other malignancies, such as conventional PTC, infiltrative FVPTC, tall cell variant PTC, oncocytic variant PTC, follicular carcinoma, or poorly differentiated carcinoma ([Table 2](#t2-jptm-2019-09-18){ref-type="table"}).

Because not all cases were available for slide review and NIFTP can be misclassified as non-PTC tumors, the lower boundary for the prevalence of NIFTP among PTCs was estimated. When the same histologic criteria was applied for the diagnosis of NIFTP regardless of the tumor size, the prevalence of NIFTP was 238 (1.3%) among all PTCs. Among the reclassified 238 NIFTP cases, 86 had a tumor \<1.0 cm and 152 had a tumor ≥1.0 cm ([Table 2](#t2-jptm-2019-09-18){ref-type="table"}). Therefore, the expected lower boundary for the prevalence of NIFTP was 0.8% (152/18,819) when tumors ≥1.0 cm were included for the diagnosis of NIFTP.

Clinicopathologic characteristics of patients with NIFTP
--------------------------------------------------------

Among 152 patients with NIFTP ≥1.0 cm in size, 125 (82.2%) patients had only NIFTP and the remaining 27 patients (17.8%) had NIFTP coexisting with thyroid cancer. The clinicopathologic characteristics were evaluated in patients with only NIFTP. The demographics of 125 NIFTP patients are shown in [Table 3](#t3-jptm-2019-09-18){ref-type="table"}. The mean age was 46.7 years (range, 23 to 73 years). The NIFTP patients included 93 females (74.4%) and 32 males (25.6%). The median primary tumor size was 26.2 mm (range, 10 to 80 mm). Among 125 patients, 101 (80.8%) underwent cervical lymph node dissection and lymph node metastasis was not found. In addition, no patient had lymphatic/vascular invasion or distant metastases. Regarding surgical methods, a total of 44 patients (35.2%) underwent total thyroidectomy and 81 patients (64.8%) received lobectomy or isthmectomy. Furthermore, 29 patients (23.2%) underwent radioactive iodine (RAI) remnant ablation therapy based on the initial tumor size. Disease recurrence was not observed in any NIFTP patient during a median follow-up period of 25.1 months.

Impact of NIFTP on pathologic examination and clinical practice
---------------------------------------------------------------

A difference in the prevalence of NIFTP before and after NIFTP introduction was not observed ([Table 3](#t3-jptm-2019-09-18){ref-type="table"}). The number of paraffin blocks for diagnosis of NIFTP did not increase after the introduction of NIFTP (average 5.2 per tumor before April 2016 and average 5.5 per tumor after April 2016).

The rate of lymph node dissection increased from 72.7% before April 2016 to 89.8% after April 2016. The rate of total thyroidectomy decreased from 43.9% before April 2016 to 25.4% after April 2016. The number of patients undergoing postoperative RAI therapy was significantly reduced from 25.8% before April 2016 to 20.3% after April 2016 ([Table 3](#t3-jptm-2019-09-18){ref-type="table"}). RAI treatment was performed due to coexisting thyroid cancers in most cases.

*BRAF* and *RAS* mutations in NIFTPs
------------------------------------

Twenty-seven patients diagnosed with *NIFTP* at the Gangnam Severance Hospital after April 2016 were randomly selected for gene analysis; *BRAF*^V600E^ mutation was not observed. As shown in [Table 4](#t4-jptm-2019-09-18){ref-type="table"}, the overall frequency of three *RAS* gene mutations was 55.6% (15/27). The mutation rates of *NRAS*, *HRAS*, and *KRAS* were 22.2%, 22.2%, and 11.1%, respectively.

DISCUSSION
==========

The overall prevalence of NIFTP was 1.3% (range, 0.4% to 2.6%) of all PTCs in the present study, which included the largest cohort size researched to date among the Korean population ([Table 1](#t1-jptm-2019-09-18){ref-type="table"}). According to the recent study by Nikiforov et al. \[[@b8-jptm-2019-09-18]\], any masses \<1.0 cm were not included in the diagnosis of NIFTP. Moreover, in another recent NIFTP study, data on the sub-centimeter NIFTP were limited \[[@b22-jptm-2019-09-18]\]. Thus, the expected lower boundary for the prevalence of NIFTP was 0.8% when tumors ≥1 cm in size were included in the diagnosis of NIFTP.

These results are consistent with the findings from a previous study in which the mean prevalence of NIFTP was 1.5% (range, 0% to 4.7%) in nine institutions from six Asian countries, including Korea \[[@b23-jptm-2019-09-18]\]. The prevalence of NIFTP is constantly lower in Asian studies than in Western population-based studies \[[@b22-jptm-2019-09-18],[@b24-jptm-2019-09-18]-[@b27-jptm-2019-09-18]\].

NIFTPs frequently have *RAS* mutations but no *BRAF*^V600E^ mutation \[[@b11-jptm-2019-09-18]-[@b14-jptm-2019-09-18]\]. However, the *BRAF*^V600E^ mutation was found in some NIFTP cases in several studies immediately performed after the initial publication of NIFTP \[[@b17-jptm-2019-09-18],[@b18-jptm-2019-09-18],[@b28-jptm-2019-09-18],[@b29-jptm-2019-09-18]\]. [Table 5](#t5-jptm-2019-09-18){ref-type="table"} summarizes the results of *BRAF* mutation in NIFTP reported in previous studies from six Korean institutions \[[@b17-jptm-2019-09-18],[@b18-jptm-2019-09-18],[@b28-jptm-2019-09-18]-[@b31-jptm-2019-09-18]\]. When the strict criterion of "0% papillae" was applied in the present study, no *BRAF* mutation was found in NIFTPs. In the present case series, a case of *BRAF*^V600E^-positive tumor originally diagnosed as non-invasive EFVPTC was found. The pathology slides were re-examined after cutting deeper sections and a true papillary structure was found in a focal area. Therefore, the case was reclassified as encapsulated classic PTC with predominant follicular growth pattern. This finding reconfirms the strict diagnostic criteria for NIFTP are helpful for excluding true PTC. Because the diagnostic criteria for NIFTP have been updated, NIFTP should no longer include any follicular patterned tumors with well-formed papillae or high-risk gene mutations such as *BRAF*^V600E^, *TERT* promoter, or *TP53* \[[@b20-jptm-2019-09-18]\].

The present study had several technical limitations. First, due to the retrospective multicenter-based nature of this study, interobserver variability in the diagnosis of NIFTP based on histology was not considered. Second, since only the cases diagnosed with PTC were included, the possibility that NIFTP was diagnosed as benign, such as nodular hyperplasia or follicular adenoma, may result in differences in actual prevalence. However, the prevalence of NIFTP did not change significantly even after the introduction of NIFTP. Third, although the overall study cohort size was relatively large, genetic analysis of *BRAF* and *RAS* mutations were performed in only a limited number of NIFTP cases. Nevertheless, the results were consistent with previous study results showing NIFTP has no *BRAF*^V600E^ mutation and frequent *RAS* mutations \[[@b8-jptm-2019-09-18],[@b15-jptm-2019-09-18],[@b20-jptm-2019-09-18]\].

The results from this study has shown the low prevalence of NIFTP among PTCs in Korea using the largest number of cases to date. Adverse outcomes were not experienced by any patient with NIFTP during the follow-up period. The introduction of NIFTP may have a small overall impact in Korean practice.
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![(A) A case of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): low power view, NIFTP composed entirely of a follicular growth pattern with complete encapsulation (scan view). (B) NIFTP shows a thick fibrous capsule without capsular and vascular invasion. (C) NIFTP with nuclear score 2. (D, E) Papillary thyroid carcinoma showing nuclear score 3.](jptm-2019-09-18f1){#f1-jptm-2019-09-18}

###### 

The prevalence of NIFTP in eight university hospitals

  Institution   Period       PTC      Invasive EFVPTC   NIFTP
  ------------- ------------ -------- ----------------- -----------
  A             2012--2017   1,427    44 (3.1)          26 (1.8)
  B             2013--2016   1,342    35 (2.6)          35 (2.6)
  C             2013--2017   3,927    192 (4.9)         100 (2.5)
  D             2013--2017   6,200    134 (2.2)         24 (0.4)
  E             2013--2017   3,083    37 (1.2)          23 (0.7)
  F             2014--2017   734      9 (1.2)           5 (0.7)
  G             2015--2017   1,077    2 (0.2)           20 (1.9)
  H             2015--2018   1,029    14 (1.4)          5 (0.5)
  Total                      18,819   467 (2.5)         238 (1.3)

Values are presented as number (%).

NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma; EFVPTC, encapsulated follicular variant of PTC.

###### 

Prevalence of NIFTP according to the tumor size among 18,819 patients with initial diagnosis of papillary thyroid carcinoma

                                     Total        ≥ 1.0 cm     \< 1.0 cm
  ---------------------------------- ------------ ------------ -----------
  All cases of NIFTP                 238 (1.3)    152 (0.8)    86 (0.5)
  NIFTP alone                        174 (73.3)   125 (82.2)   49 (57.0)
  NIFTP coexisting with malignancy   64 (26.7)    27 (17.8)    37 (43.0)

Values are presented as number (%).

NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features.

###### 

Demographic and clinicopathologic features of 125 patients with NIFTP alone before and after NIFTP introduction

                                                               Overall                Before NIFTP introduction^[a](#tfn1-jptm-2019-09-18){ref-type="table-fn"}^   After NIFTP introduction   p-value
  ------------------------------------------------------------ ---------------------- ---------------------------------------------------------------------------- -------------------------- ---------
  Prevalence of NIFTP                                          125/18,819 (0.7)       66/9,656 (0.6)                                                               59/9,163 (0.7)             .739
  Sex                                                                                                                                                                                         .004
   Male                                                        32 (25.6)              24 (36.4)                                                                    8 (13.6)                   
   Female                                                      93 (74.4)              42 (63.6)                                                                    51 (86.4)                  
  Age, mean ± SD (range, yr)                                   46.7 ± 12.5 (23--73)   47.9 ± 13.1 (23--73)                                                         45.3 ± 11.9 (25--73)       .238
  Tumor size, median (range, mm)                               26.2 (10--80)          24.5 (10--61)                                                                28.0 (10--80)              .195
  No. of paraffin blocks, median (range)                       5.3 (1--26)            5.2 (2--26)                                                                  5.5 (1--18)                .398
  Lymph node dissection                                                                                                                                                                       .385
   Performed                                                   101 (80.8)             48 (72.7)                                                                    53 (89.8)                  
   Not performed                                               24 (19.2)              18 (27.3)                                                                    6 (10.2)                   
  Lymph node metastases                                                                                                                                                                       \> .99
   Positive                                                    0                      0                                                                            0                          
   Negative^[b](#tfn2-jptm-2019-09-18){ref-type="table-fn"}^   125 (100)              66 (100)                                                                     59 (100)                   
  Surgical procedure                                                                                                                                                                          .021
   Lobectomy or isthmectomy                                    81 (64.8)              37 (56.1)                                                                    44 (74.6)                  
   Total thyroidectomy                                         44 (35.2)              29 (43.9)                                                                    15 (25.4)                  
  Lymphatic invasion                                                                                                                                                                          1.000
   Positive                                                    0                      0                                                                            0                          
   Negative                                                    125 (100)              66 (100)                                                                     59 (100)                   
  Vascular invasion                                                                                                                                                                           1.000
   Positive                                                    0                      0                                                                            0                          
   Negative                                                    125 (100)              66 (100)                                                                     59 (100)                   
  Distant metastasis                                                                                                                                                                          1.000
   Positive                                                    0                      0                                                                            0                          
   Negative                                                    125 (100)              66 (100)                                                                     59 (100)                   
  Postoperative radioactive iodine therapy                                                                                                                                                    .365
   Performed                                                   29 (23.2)              17 (25.8)                                                                    12 (20.3)                  
   Not performed                                               96 (76.8)              49 (74.2)                                                                    47 (79.7)                  
  Follow-up, median ± SD (range, mo)                           25.1 ± 19.1 (0--60)    36.2 ± 14.5 (0--60)                                                          10.7 ± 6.6 (1--24)         
  Recurrence of disease                                                                                                                                                                       1.000
   Positive                                                    0                      0                                                                            0                          
   Negative                                                    125 (100)              66 (100)                                                                     59 (100)                   

Values are presented as number (%) unless otherwise indicated.

NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; SD, standard deviation.

Before April, 2016;

Includes pN0 and pNx stages.

###### 

Molecular profiles of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (n = 27)

  Mutation                                                                      No. (%)
  ----------------------------------------------------------------------------- -----------
  *BRAF*^V600E^                                                                 
   Present                                                                      0
   Absent                                                                       27 (100)
  All *RAS* mutation                                                            
   Present                                                                      15 (55.6)
  *  NRAS*                                                                      6 (22.2)
     c.181C \> A (p.Gln61Lys)                                                   3 (50.0)
     c.182A \> G (p.Gln61Arg)                                                   3 (50.0)
  *  HRAS*                                                                      6 (22.2)
     c.182A \> G (p.Gln61Arg)                                                   6 (100)
    *KRAS* codon 61 mutation^[a](#tfn3-jptm-2019-09-18){ref-type="table-fn"}^   3 (11.1)

*KRAS* mutation was analyzed by PNAClamp *KRAS* mutation detection kit.

The assay cannot identify specific mutation types.

###### 

Characteristics of NIFTP in Korean population reported in literature

  Study                                          Period       Diagnostic criteria   PTC     NIFTP          No. (%)                            
  ---------------------------------------------- ------------ --------------------- ------- -------------- ----------- ----------- ---------- ---------
  Cho et al. (2017) \[[@b17-jptm-2019-09-18]\]   2008--2014   \< 1% papillae        6,269   105            10 (10.0)   \-          3 (2.9)    1 (1.0)
  0% papillae                                    6,269        95                    0       48/89 (53.9)   2 (2.1)     0                      
  Kim et al. (2017) \[[@b28-jptm-2019-09-18]\]   2009--2014   \< 1% papillae        6,548   43             3 (7.0)     \-          1 (2.3)    0
  Lee et al. (2017) \[[@b18-jptm-2019-09-18]\]   2010--2014   \< 1% papillae        769     21             5 (23.8)    12 (57.1)   1 (4.7)    0
  Kim et al. (2018) \[[@b30-jptm-2019-09-18]\]   2011--2012   \< 1% papillae        1,411   2              0           \-          0          0
  Kim et al. (2018) \[[@b31-jptm-2019-09-18]\]   2013--2016   0% papillae           \-      32             0           15 (46.9)   0          0
  Kim et al. (2018) \[[@b29-jptm-2019-09-18]\]   2014--2016   \< 1% papillae        2,853   73             9 (12.3)    36 (49.3)   9 (12.3)   0

NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma.
